报价延迟最少15分钟:2026/03/06 23:49 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.45 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
279.15/-3.09
|
|
企业价值
180.35M
|
| 资产负债 |
|
每股账面净值
18.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.09M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Tonix Pharmaceuticals Holding Corp is a commercial-stage biotechnology company focused on the development and commercialization of treatments for central nervous system (CNS) disorders and immunological conditions. Its product portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. |
